Revenue: As of FY2025, the actual value is USD 0.EPS: As of FY2025, the actual value is USD -0.53, missing the estimate of USD -0.5163.EBIT: As of FY2025, the actual value is USD -127.71 M.Savara Inc. operates in a single segment, focusing on specialty pharmaceuticals within the respiratory system, and therefore does not report segmented financial metrics .<h4>Operational Metrics (YoY Comparison)</h4><ul><li>Net Loss: Savara Inc. reported a net loss of -$118.8 million for the year ended December 31, 2025, an increase from -$95.9 million for the year ended December 31, 2024 .</li><li>Research and Development Expenses: These expenses increased by $3.4 million, or 4.3%, to $81.4 million for the year ended December 31, 2025, compared to $78.0 million for the year ended December 31, 2024 . This increase was primarily due to $5.7 million in regulatory affairs and quality assurance costs, $0.5 million in chemistry, manufacturing, and controls activities, and $1.0 million in other departmental overhead, partially offset by a -$3.8 million decrease in clinical costs .</li><li>General and Administrative Expenses: These expenses increased by $17.0 million, or 68.0%, to $42.1 million for the year ended December 31, 2025, from $25.0 million for the year ended December 31, 2024 . This rise was driven by $11.2 million in higher personnel and related costs, $3.1 million for certain commercial activities, and $2.7 million in other overhead .</li><li>Depreciation and Amortization: This decreased to $87 thousand for the year ended December 31, 2025, from $130 thousand in 2024 .</li><li>Total Operating Expenses: Total operating expenses were $123.5 million in 2025, up from $103.2 million in 2024 .</li><li>Other Income, Net: Other income, net decreased by -$2.6 million to $4.7 million for the year ended December 31, 2025, from $7.3 million for the year ended December 31, 2024, primarily due to lower interest income and a -$546 thousand loss on extinguishment of debt .<ul><li>Interest Income, Net: $4.2 million in 2025 compared to $6.5 million in 2024 .</li><li>Foreign Currency Exchange Gain: $310 thousand in 2025 compared to $51 thousand in 2024 .</li><li>Tax Credit Income: $784 thousand in 2025 compared to $797 thousand in 2024 .</li><li>Loss on Extinguishment of Debt: -$546 thousand in 2025 compared to $0 in 2024 .</li></ul></li></ul><h4>Cash Flow</h4><ul><li>Cash Used in Operating Activities: -$101.0 million for the year ended December 31, 2025, compared to -$89.1 million for the year ended December 31, 2024 .</li><li>Cash Used in Investing Activities: -$18.4 million for the year ended December 31, 2025, compared to -$39.9 million for the year ended December 31, 2024 .</li><li>Cash Provided by Financing Activities: $137.8 million for the year ended December 31, 2025, compared to $117.6 million for the year ended December 31, 2024 .</li></ul><h4>Balance Sheet Metrics (as of December 31, 2025)</h4><ul><li>Cash and Cash Equivalents: $33.2 million .</li><li>Short-term Investments: $202.5 million .</li><li>Accumulated Deficit: -$608.1 million .</li><li>Working Capital: $221.2 million .</li><li>Long-term Debt: $29.9 million .</li></ul><h4>Outlook / Guidance</h4>Savara Inc. anticipates substantial operating losses in the foreseeable future due to the clinical development, regulatory approvals, and commercialization of its MOLBREEVI product candidate . Research and development expenses are expected to remain significant, driven by increased investment in regulatory support and contract manufacturing . The company plans to meet future funding requirements through existing capital, equity offerings, debt financings, and strategic alliances .

Savara | 10-K: FY2025 Revenue: USD 0